Welcome to our dedicated page for Century Therapeutics SEC filings (Ticker: IPSC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Century Therapeutics’ SEC filings rarely read like simple financial statements. Each 10-K weaves stem-cell science, Allo-Evasion™ gene edits and cash-burn projections into 200+ pages, leaving investors hunting for clear answers. Stock Titan fixes that problem.
Our AI-powered reader turns every Century Therapeutics SEC filing into plain-English insights. Want the latest “Century Therapeutics quarterly earnings report 10-Q filing” summarized before the market opens? We tag key figures—R&D spend, clinical trial milestones, liquidity runway—and deliver context in seconds. Need “Century Therapeutics insider trading Form 4 transactions” alerts? Real-time feeds flag executive stock moves, so you can follow “Century Therapeutics executive stock transactions Form 4” without refreshing EDGAR.
You’ll find every document, from the “Century Therapeutics annual report 10-K simplified” to “Century Therapeutics 8-K material events explained,” all indexed the moment they hit the SEC. Our platform connects forms to what matters for this particular biotech:
- 10-K: Pipeline status, manufacturing capacity and Allo-Evasion™ IP disclosures
- 10-Q: Quarterly cash burn and trial read-outs
- 8-K: Partnership deals, FDA designations and clinical setbacks
- DEF 14A proxy: “Century Therapeutics proxy statement executive compensation” showing R&D incentive structures
- Form 4: “Century Therapeutics Form 4 insider transactions real-time” for sentiment signals before data drops
Stop scrolling through dense PDFs. Stock Titan’s expert analysis, natural-language summaries and adjustable redline comparisons let you understand “Century Therapeutics SEC filings explained simply” and act on them faster.
Radius Recycling, Inc. (RDUS) – SEC Form 4 insider filing
Director Gregory R. Friedman reported the disposition of his entire equity position in connection with the completion of Radius Recycling’s merger with Toyota Tsusho America, Inc. on July 10 2025.
- Transaction: Disposition (Code D) of 18,739.541 shares of Class A common stock on 07/10/2025.
- Consideration: Each share was converted into the right to receive $30.00 in cash pursuant to the Agreement and Plan of Merger dated 03/13/2025.
- Deferred Stock Units: The total includes 9,607 unvested DSU awards that vested immediately at closing and were cancelled for the same cash amount plus accrued dividend equivalents.
- Post-transaction ownership: Mr. Friedman now holds 0 RDUS shares; no derivative securities were reported.
The filing confirms that Radius Recycling is now a wholly-owned subsidiary of Toyota Tsusho America and that all public shares have been converted to cash.
Bank of Montreal (BMO) is offering auto-callable Market Linked Securities tied to the lowest performing share among Advanced Micro Devices (AMD), Amazon.com (AMZN) and Alphabet Class A (GOOGL). Each security has a $1,000 face amount, will be priced on July 18 2025 and issued on July 23 2025.
Early call feature: if on the July 23 2026 call date the lowest-performing Underlier closes at or above 90 % of its starting value, the notes are automatically redeemed for $1,000 plus a call premium of at least 25.35 %. Investors then forgo all further upside.
At maturity (July 21 2028) if not called:
- Upside: 200 % participation in any gain of the worst Underlier.
- Contingent absolute return: if that Underlier ends ≤ its start but ≥ 55 %, holders receive a positive payout equal to the absolute decline (maximum 45 %).
- Downside: if it finishes below 55 %, investors are fully exposed to the loss and can lose up to 100 % of principal.
FAQ
What is the current stock price of Century Therapeutics (IPSC)?
What is the market cap of Century Therapeutics (IPSC)?
What is the core business of Century Therapeutics?
What does Allo-Evasion™ technology do?
How does Century Therapeutics’ approach differ from first-generation cell therapies?
What are the primary therapeutic targets of Century Therapeutics?
How are iPSC-derived therapies beneficial?
What role does genetic engineering play in their technology platform?
Why is repeat dosing important in cell therapies?
What additional services does Century Therapeutics offer?
